With over two decades of experience in senior scientific and leadership roles across the biotechnology and pharmaceutical sectors, Dr. Sinclair will now lead LabGenius Therapeutics’ drug discovery and preclinical development activities.
LONDON, United Kingdom — 29/05/25. LabGenius Therapeutics (“LabGenius”) is a drug discovery company combining machine learning (ML) and high-throughput experimentation to optimise complex therapeutic antibodies, including those with multispecific designs. The company today announced the appointment of Dr. Angus Sinclair as Chief Scientific Officer (CSO). In this role, Dr. Sinclair will leverage his wealth of drug discovery and development experience to lead LabGenius’ scientific strategy, driving pipeline and platform innovation. Dr. Sinclair succeeds Dr. Gino Van Heeke, the former CSO, who is retiring, and, after ensuring a smooth leadership transition, will continue to support the company as a Scientific Advisor.
Angus joins LabGenius from IGM Biosciences, where, as Executive Vice President, Research, he led the advancement of more than 15 novel, potent antibody-based therapeutics from proof-of-concept, through preclinical development, achieving multiple IND filings. Before this, Angus was Senior Director, Oncology Research at Northern Biologics (assets acquired by Boehringer Ingelheim and AstraZeneca), where he directed the validation of novel oncology targets. Previously, Angus held several senior positions at Amgen over a 13-year tenure, including Scientific Director, Oncology Research.
“I’m delighted to welcome Angus to the team,” commented LabGenius’ CEO, Dr. James Field. “He joins us at an exciting time, as our internal programmes continue to generate increasingly compelling data. These results, coupled with Angus’ impressive track record of advancing drug candidates into preclinical and clinical development, will help further accelerate the company’s progress. I would also like to express my gratitude to Gino for his unwavering dedication to LabGenius. His expertise and leadership have been instrumental in the discovery and development of the solid tumour-targeting antibodies in our rapidly progressing pipeline.”
Speaking about his appointment as CSO, Dr. Sinclair said, “The LabGenius team has built an impressive closed-loop discovery platform, EVA™, which identifies high-performing antibody designs that address key limitations of current solid tumour treatments, including on-target, off-tumour toxicity. I’m excited to join the company and contribute my expertise to help unlock the full potential of these next-generation antibodies.”
About LabGenius Therapeutics
LabGenius Therapeutics (“LabGenius”) is a drug discovery company pioneering the discovery of next-generation therapeutic antibodies. The company’s discovery platform, EVA™, integrates several cutting-edge technologies drawn from the fields of artificial intelligence, robotic automation and synthetic biology. LabGenius Therapeutics operates a hybrid business model that includes partnering with biotech and pharmaceutical companies in parallel with pursuing a wholly-owned therapeutic pipeline. For more information, please visit www.labgeniustx.com, or connect on LinkedIn, X, and Blusky.
Contacts
Media: press@labgeni.us
Corporate / business development: partnerships@labgeni.us
